On November 10, 2026 Adcendo ApS ("Adcendo"), a biotech company focused on developing a pipeline of differentiated antibody-drug conjugates (ADCs) for cancers with high unmet medical need, reported a late-breaking oral presentation highlighting initial clinical data from the ongoing Phase 1 ADCElerate1 trial evaluating ADCE-D01, a first-in-class ADC against the novel target uPARAP, in patients with advanced soft tissue sarcoma, at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), taking place November 18-20, 2026, in Barcelona, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation Details:
Title: A novel antibody-drug conjugate targeting urokinase plasminogen activator receptor-associated protein in previously treated patients with advanced soft tissue sarcoma: emerging clinical results from the phase 1 ADCElerate1 study (NCT06797999)
Presenter: Dr. Patrick Schöffski, University Hospitals Leuven and KU Leuven, Belgium
Session: Plenary Session 3 – Proffered Papers: Clinical Trials
Abstract number: 4LBA
Date and time: Thursday, November 19, 2026, at 10:00 a.m. CET / 4:00 a.m. ET
(Press release, ADCendo, NOV 10, 2026, View Source [SID1234674550])